Lead Discovery Center Gmbh

Max-planck-gesellschaft Zur F&#xf6;rderung Der Wissenschaften E. V.

Bayer Intellectual Property Gmbh

Bayer Pharma Aktiengesellschaft

Sotio A.s.

Ingenium Pharmaceuticals Gmbh

Qli5 Therapeutics Ag

Bert Klebl

Axel Choidas

Uwe Koch

Peter Nussbaumer

Wilfried Schwab

Jan Eickhoff

Anke Unger

Axel Ullrich

Michael A Pleiss

Ulrich Lücking

Jaeseung Kim

Tim Bergbrede

Raffaella Di Lucrezia

Nils-Göran Larsson

Claes M Gustafsson

Maria Falkenberg-Gustafsson

Don Simpson

Joelle Le

Jackie Macritchie

Zoltán Greff

Carsten Schultz-Fademrecht

Martin Augustin

Hans Allgeier

Gerd Rühter

Heike Schauerte

Philipp Wabnitz

Gabriele Stumm

Edmund Hoppe

Lutz Zeitlmann

Doris Hafenbradl

Gerhard Müller

Anke Mueller

Klaus Godl

Carsten Schulz-Fademrecht

Gerhard Mueller

Jeongjea Seo

Brad Sherborne

Vladimir Savic

John Harris

Jose Bravo

Birgit Zech

Andrea Missio

Roman Thomas

Christian Hartung

Peter Habenberger

Achim Freisleben

Beatrice Felber

Ola Engkvist

Matt Cotten

Alexander Backes

Alexander Wolf

Thomas Herget

Robert Huber

Wongyun Ahn

Seung-Joo Lee

Julian Engel

Matthias Baumann

Carsten Degenhart

The invention provides novel coumarin derivatives as specific mitochondrial RNA polymerase inhibitors for the treatment of cancer.

Coumarin derivatives, processes for their preparation and uses thereof for the treatment of cancer

The invention provides novel 4-phenyl-coumarin derivatives, processes for their preparation and uses thereof as specific mitochondrial RNA polymerase inhibitors for the treatment of cancer.

4-phenyl-coumarin derivatives, processes for their preparation and uses thereof for the treatment of cancer

The present invention relates to disubstituted pyridine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke, and pharmaceutical compositions containing at least one of said disubstituted pyridine derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said disubstituted pyridine derivatives as inhibitors for a protein kinase.

Pharmaceutically active disubstituted pyridine derivatives

The present invention relates to 1-nitrogen-heterocyclic-2-carboxamides and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the treatment and/or prevention of Axl receptor tyrosine kinase subfamily induced disorders, including cancer and primary tumor metastases, and pharmaceutical compositions containing at least one of said 1-nitrogen-heterocyclic-2-carboxamide derivatives and/or pharmaceutically acceptable salts thereof.

Pharmaceutically active compounds as Axl inhibitors

The present invention relates to inhibitors of general Formula (I) of cyclin-dependent kinases and therapeutic applications thereof. Furthermore, the invention relates to compounds for preventing and/or treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases.

4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases

The present invention relates to 4,6-disubstituted aminopyrimidine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, prion diseases, immunological diseases, autoimmune diseases, bipolar and clinical disorders, cardiovascular diseases, cell proliferative diseases, diabetes, inflammation, transplant rejections, erectile dysfunction, neurodegenerative diseases and stroke, and pharmaceutical compositions containing at least one of said 4,6-di substituted aminopyrimidine derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said 4,6-disubstituted aminopyrimidine derivatives as inhibitors for a protein kinase and a medium comprising at least one of said 4,6-disubstituted aminopyrimidine derivatives in an immobilized form and the use of said medium for enriching, purifying and/or depleting nucleotide binding proteins which bind to the immobilized 4,6-disubstituted aminopyrimidine derivatives.

Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases

Growing community of inventors

Dortmund, Germany

Bert Klebl